Search

Your search keyword '"Roche Holding AG -- Product information"' showing total 135 results
Start Over Descriptor "Roche Holding AG -- Product information"
135 results on '"Roche Holding AG -- Product information"'

1. Product information

Subjects
Middleware -- Product information, Cellular telephone services industry -- Product information, Instrument industry -- Product information, Pharmaceutical industry -- Product information, Quality control -- Product information, Middleware, Wireless telecommunications service, Database middleware, Quality control, Sunquest Information Systems Inc. -- Product information, Unity Cellular Inc. -- Product information, bioMérieux Inc. -- Product information, IRIS International Inc. -- Product information, Beckman Coulter Inc. -- Product information, DRG International Inc. -- Product information, Roche Holding AG -- Product information
Abstract

5301 Buckeystown Pike, Suite 350 Frederick, MD 21704 Ordering/Pricing/Product Information Phone: (301)644-3248 Fax: (240) 454-9449 Website: www.A2LA.org Email: info@A2LA.org Raising the Bar in Laboratory Quality ... A2LA boasts over 35 […]

Published
2014

2. Tocilizumab: a humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis

Author

Schlesselman, Lauren S. and Hussey, Aaron P.

Subjects
Roche Holding AG -- Product information, Actemra (Medication) -- Product information -- Dosage and administration -- Complications and side effects, Rheumatoid arthritis -- Drug therapy -- Product information -- Complications and side effects, Pharmaceutical industry -- Product information, Pharmaceuticals and cosmetics industries, Drug therapy, Complications and side effects, Product information, Dosage and administration
Abstract

Abstract Despite the numerous medications available to control the signs and symptoms and prevent the progression of rheumatoid arthritis (RA), many patients' symptoms are not adequately controlled with available therapies. [...]

Published
2008

3. 16A Nonnarcotic analgesics

Subjects
Bayer HealthCare L.L.C. Consumer Care Div. -- Product information, Roche Holding AG -- Product information, Wyeth Consumer Healthcare Inc. -- Product information, Pain -- Care and treatment -- Product information, Pharmaceutical industry -- Product information, Health, Bayer Aspirin (Medication) -- Dosage and administration -- Product information, Anaprox (Medication) -- Dosage and administration -- Product information, Advil (Medication) -- Dosage and administration -- Product information
Abstract

PRESCRIBING NOTES For NSAIDs for arthritis and dysmenorrhea see Sections 12A and 15D, respectively. The doses of these drugs should be individualized. ADVIL Wyeth Cons. OTC NSAID (propionic acid deriv.). [...]

Published
2006

4. Rescue Use of DNase in Critical Lung Atelectasis and Mucus Retention in Premature Neonates

Author

EL HASSAN, NAHED O., CHESS, PATRICIA R., HUYSMAN, MARIANNE W. A., MERKUS, PETER J. F. M., and DE JONGSTE, JOHAN C.

Subjects
Roche Holding AG -- Product information, Pulmozyme (Medication) -- Evaluation, Atelectasis -- Drug therapy, Infants (Premature) -- Care and treatment
Abstract

Excessive or thick pulmonary secretions are a common clinical challenge in the neonatal population. Mucus accumulation can cause many life-threatening complications, including plugging of the endotracheal tube and increasing the risk of pulmonary infections. We report 3 premature neonates who had critical pulmonary collapse secondary to mucous plugging. Different conventional methods to liquefy mucus and facilitate removal of secretions were exhausted to no avail. The rescue use of DNase was effective in reestablishing airway patency. Thus, this drug could be a valuable tool in treating atelectasis and mucus-plugging in mechanically ventilated, premature neonates. Pediatrics 2001;108:468-471; rhDNase, Dornase alfa, atelectasis, infection, bronchopulmonary dysplasia., ABBREVIATIONS. RDS, respiratory distress syndrome; PDA, persistent ductus arteriosus, BPD, bronchopulmonary dysplasia; HFOV, high-frequency oscillatory ventilation. Excessive or thick pulmonary secretions and mucus-plugging are common clinical challenges in the neonatal [...]

Published
2001

5. Avian Flu Update

Author

Fox, Steven

Subjects
Roche Holding AG -- Product information, Tamiflu (Medication) -- Usage -- Product information, Control, Usage, Product information, Epidemics -- Control -- Switzerland -- Product information, Avian influenza -- Control -- Product information -- Usage, Pharmaceutical industry -- Product information -- Usage
Published
2006

6. Drug alert

Author

Stein, Lisa

Subjects
United States. Food and Drug Administration -- Analysis, Vioxx (Medication) -- Adverse and side effects, Vioxx (Medication) -- Product information, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Analysis, AstraZeneca PLC -- Product information, GlaxoSmithKline Inc. (Research Triangle Park, North Carolina) -- Product information, GlaxoSmithKline Inc. (Research Triangle Park, North Carolina) -- Analysis, Roche Holding AG -- Product information
Published
2004

7. Valganciclovir

Subjects
Roche Holding AG -- Product information, Valcyte (Medication) -- Evaluation -- Product information -- Product/service Evaluations, Valganciclovir -- Evaluation -- Product information -- Product/service Evaluations, Cytomegalovirus infections -- Prevention -- Product information, Pharmaceutical industry -- Product information, Pharmaceuticals and cosmetics industries, Prevention, Evaluation, Product information
Abstract

Valganciclovir (Valcyte, Roche) received supplemental approval as a preventive treatment for cytomegalovirus (CMV) disease in high-risk kidney, kidney-pancreas, and heart transplant [...]

Published
2003

8. OTC: Periods seen as art

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Analgesics -- Product information, Menstruation -- Care and treatment, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

The average woman spends more than five years of her life having a period and Roche, manufacturer of Feminax, the period pain relief product, felt it was time to take [...]

Published
2003

9. Therapy with the recently approved peginterferon alfa-2a (Pegasys, Roche) in combination with ribavirin (Copegus, Roche) has been approved for treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been treated with interferon alpha before

Subjects
Roche Holding AG -- Product information, Copegus (Medication) -- Evaluation -- Product information -- Product/service Evaluations, Pegasys (Medication) -- Evaluation -- Product information -- Product/service Evaluations, Ribavirin -- Dosage and administration -- Evaluation -- Product information -- Product/service Evaluations, Hepatitis C -- Care and treatment -- Product information, Pharmaceutical industry -- Product information, Pharmaceuticals and cosmetics industries, Care and treatment, Evaluation, Product information, Dosage and administration
Abstract

Therapy with the recently approved peginterferon alfa-2a (Pegasys, Roche) in combination with ribavirin (Copegus, Roche) has been approved for treatment of adults with chronic hepatitis C who have compensated liver [...]

Published
2003

10. Palfium shortage

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Analgesics -- Product information, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Roche has announced that stocks of Palfium (dextromoramide) tablets will run out by late December due to manufacturing problems. It is anticipated that 5mg tablets will be back in stock [...]

Published
2002

11. Legal status of black box warnings in package inserts. (Rx Legal Q&A)

Subjects
Government regulation, Pharmacists Mutual Insurance Co. -- Reports, Roche Holding AG -- Product information, Roche Holding AG -- Laws, regulations and rules, Accutane (Medication) -- Laws, regulations and rules, Accutane (Medication) -- Labeling, Pharmaceutical industry, Drugs -- Prescribing
Abstract

If you have a practice-related legal question, please e-mail it to drug.topics@medec.com. We will get you a response from Ken Baker, R.Ph., J.D., v.p. and general counsel at Pharmacists Mutual [...]

Published
2002

12. Breast cancer use for Xeloda

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Xeloda (capecitabine) from Roche is now licensed for the treatment of breast cancer. Used in combination with docetaxel, it is indicated for patients with locally advanced or metastatic breast cancer [...]

Published
2002

15. Acne drug in the news again

Subjects
Roche Holding AG -- Product information, Accutane (Medication) -- Psychological aspects, Pharmaceutical industry -- Product information
Abstract

Investigators are exploring whether the Florida teenager who crashed an airplane into a high-rise in Tampa, Fla., could have been influenced by a drug for which he had a prescription. [...]

Published
2002

16. New combo may extend breast cancer survival

Author

Ritz, Jayne

Subjects
Roche Holding AG -- Product information, Aventis S.A. -- Product information, Xeloda (Medication) -- Research, Taxotere (Medication) -- Research, Pharmaceutical industry -- Product information, Breast cancer -- Care and treatment
Abstract

Until recently, only minimal treatment options have been available for patients with metastatic breast cancer (MBC) who have failed an anthracycline-based chemotherapy. Last month, the Food & Drug Administration approved [...]

Published
2001

17. Xeloda/Taxotere breast cancer therapy gets FDA endorsement

Subjects
Roche Holding AG -- Product information, Aventis Pharmaceuticals Inc. -- Product information, Pharmaceutical industry -- Laws, regulations and rules, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

The Food and Drug Administration approved a combination cancer therapy using the oral drug Xeloda (capecitabine) from Roche and the intravenous drug Taxotere (docetaxel) from Aventis. The combination is intended [...]

Published
2001

18. Orlistat Cut Weight, Glucose Levels In Insulin-Treated Type 2 Diabetics

Author

Tucker, Miriam E.

Subjects
Roche Holding AG -- Product information, Obesity -- Drug therapy -- Product information, Orlistat -- Evaluation -- Product information -- Product/service Evaluations, Health, Health care industry, Xenical (Medication) -- Evaluation -- Product information -- Product/service Evaluations
Abstract

PHILADELPHIA -- Orlistat prompted significant weight loss and improved blood glucose control in overweight, insulin-treated patients with type 2 diabetes, Dr. George Bray reported at the annual scientific sessions of [...]

Published
2001

19. Roche

Subjects
Roche Holding AG -- Product information, Givaudan Corp. -- Product information, Tetra Pak International S.A. -- Product information, Food additives industry -- Product information, Packaging industry -- Product information, Dairy industry -- Product development, Agricultural industry, Business, Food and beverage industries
Abstract

Roche has combined resources with two other global leaders in order to provide the industry with a total product development and marketing solution for fortified products. The 'One Solution' approach [...]

Published
2001

20. FDA grants clearance for Roche's colorectal cancer treatment

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Retail industry, Xeloda (Medication) -- Laws, regulations and rules
Abstract

Roche received FDA approval May 1 to market Xeloda (capecitabine), the first oral chemotherapy for the treatment of metastatic colorectal cancer. It is only the second treatment for colorectal cancer [...]

Published
2001

21. Weight loss pill offers added health benefits

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Weight loss -- Drug therapy, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Xenical (Medication) -- Research
Abstract

An extensive study has shown that orlistat (Xenical) is effective for producing weight loss and also offers health benefits. The drug, which works without suppressing the appetite, was shown in [...]

Published
2001

22. Roche

Subjects
Roche Holding AG -- Product information, deCODE genetics Inc. -- Management, Drug approval -- Analysis, Pharmaceutical industry -- Product information, Biotechnology industry -- Management, Business, Chemicals, plastics and rubber industries, NeoRecormon (Medication) -- Laws, regulations and rules
Published
2001

23. Second consent form needed for Accutane

Subjects
Roche Holding AG -- Product information, Acne -- Care and treatment, Isotretinoin -- Dosage and administration, Pharmaceutical industry -- Dosage and administration, Business, Pharmaceuticals and cosmetics industries, Retail industry, Accutane (Medication) -- Dosage and administration
Abstract

Before beginning Accutane (isotretinoin), patients will be required to inform their physician whether they or family members have experienced symptoms of depression, such as irritability, withdrawal, crying spells, thoughts of [...]

Published
2001

24. Roche

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Colorectal cancer, Antineoplastic agents -- Marketing, Business, Chemicals, plastics and rubber industries, Xeloda (Medication) -- Marketing
Published
2001

25. Organ transplant drug gains new indication

Subjects
Roche Holding AG -- Product information, United States. Food and Drug Administration -- Laws, regulations and rules, CellCept (Medication) -- Product introduction, Pharmaceutical industry -- Product information, Kidneys -- Transplantation, Graft rejection -- Prevention, Heart -- Transplantation, Liver -- Transplantation
Abstract

Roche's Cellcept (mycophenolate mofetil) has received FDA clearance for preventing rejection in youngsters receiving kidney transplants. The compound was first approved in 1995 for preventing kidney transplant rejection in adults. [...]

Published
2001

26. Vitamin E Reaps Benefits From Mad Cow Concerns

Author

JARVIS, LISA

Subjects
Roche Holding AG -- Product information, Dietary supplements industry -- Market share, Vitamin E -- Supply and demand, Business, Chemicals, plastics and rubber industries
Abstract

Market gains from use of alternate feed additives. THE VITAMIN E market got an unexpected boost from the bovine spongiform en-cephalopathy (BSE), or mad cow disease, scare. After several years [...]

Published
2001

27. Tougher controls on Accutane

Subjects
United States. Food and Drug Administration -- Investigations, Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Birth defects -- Risk factors, Business, Chemicals, plastics and rubber industries, Accutane (Medication) -- Health aspects
Published
2000

28. Severe acne treatment causes birth defects

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Business, Chemicals, plastics and rubber industries, Accutane (Medication) -- Adverse and side effects
Published
2000

29. Blood Glucose Meter

Subjects
Roche Holding AG -- Product information, Blood sugar monitoring -- Equipment and supplies
Abstract

The Accu-Chek Simplicity blood glucose monitoring system helps diabetes patients track their blood sugar levels, yielding results from a small blood sample in as little as 25 seconds, according to [...]

Published
1999

30. Oseltamivir becomes plentiful--but still not cheap: the shortage of oseltamivir may soon be a thing of the past. But whether the drug will become cheap enough for developing countries and how well it will work against a pandemic remain to be seen

Author

Enserink, Martin

Subjects
Oseltamivir (Medication) -- Growth, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Management, Company business management, Company growth, Roche Holding AG -- Product information, Roche Holding AG -- Management
Published
2006

31. Ticlid/Plavix formulary evaluation

Author

Hayes, Jamie

Subjects
Bristol-Myers Squibb Co. -- Product information, Roche Holding AG -- Product information, Sanofi-Synthelabo S.p.A. -- Product information, Clopidogrel -- Evaluation, Ticlopidine -- Evaluation, Health care industry, Pharmaceuticals and cosmetics industries, Plavix (Medication) -- Evaluation, Ticlid (Medication) -- Evaluation
Abstract

Jamie Hayes (*) Platelet aggregation inhibitors Clopidogrel (Plavix) -- Bristol-Myers-Squibb/Sanofi Ticlopidine (Ticlid) -- Roche Mechanism of action Both drugs selectively inhibit adenosine diphosphate (ADP)-induced platelet aggregation with no direct effect [...]

Published
2001

32. Rare brain condition concern with Avastin

Subjects
Genentech Inc. -- Product information, Roche Holding AG -- Product information, Brain diseases -- Causes of, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Avastin (Medication) -- Complications and side effects
Abstract

The details pertaining to two reports published in the New England Journal of Medicine, showing a link between Genentech/Roche's anti-angiogenesis product, Avastin (bevacizumab) with a rare brain condition, are presented.

Published
2006

33. Xenical halts type 2 diabetes. (Roche's anti-obesity drug)

Author

Yost, Nicole

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Weight reducing preparations -- Health aspects, Obesity -- Complications, Type 2 diabetes -- Prevention, Business, Pharmaceuticals and cosmetics industries, Xenical (Medication) -- Health aspects
Abstract

Information on the use of Roche's obesity treatment Xenical to prevent type 2 diabetes in obese patients is offered. Additional information on the drug's therapeutic efficiency is included.

Published
2002

34. Setback for Roche

Subjects
Roche Holding AG -- Product information, Avastin (Medication) -- Testing -- Product information, Mandatory drug testing -- Product information, Pharmaceutical industry -- Product information, Environmental issues, Science and technology, Zoology and wildlife conservation, Testing, Product information
Abstract

Avastin fails in colon cancer trials. [...]

Published
2009

35. Generics challenge Roche's Tamiflu claims

Author

Zamiska, Nicholas and Dean, Jason

Subjects
Cipla Ltd. -- Product development, Cipla Ltd. -- Reports, Roche Holding AG -- Public relations, Roche Holding AG -- Product information, Influenza vaccines -- Reports, Influenza vaccines -- Product development, Pharmaceutical industry -- Public relations, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Reports, Company public relations, Banking, finance and accounting industries, Business, Business, international
Abstract

An avian influenza vaccine, Tamiflu, has been reproduced by Cipla Ltd. of India quickly and easily, contrary to reports by Roche Holding Ltd. that it would take years to copy the medication as a generic. Reports of easy vaccine production ease fears of an avian flu pandemic.

Published
2005

36. Brazil will not break drug patent. (International Developments)

Author

Boyarski, Jason R., Fishman, Rene M., Lawrence, James D., Linn, Jane, and Young, Tamir

Subjects
Roche Holding AG -- Product information, Drugs -- Intellectual property, AIDS (Disease) -- Drug therapy, Pharmaceutical industry -- Intellectual property, Law
Abstract

Brazil has announced that it will not go forward with plans to break valid patents by making a generic version of a popular AIDS drug. Rather, the Brazilian government reached [...]

Published
2001

37. Alternative medicine: a big drug maker moves to play down mass-market pills

Author

Whalen, Jeanne

Subjects
Roche Holding AG -- Licensing agreements, Roche Holding AG -- Officials and employees, Roche Holding AG -- Management, Roche Holding AG -- Product information, Roche Holding AG -- Alliances and partnerships, Trimeris Inc. -- Product development, Trimeris Inc. -- Alliances and partnerships, Biotechnology industry -- Product development, Biotechnology industry -- Alliances and partnerships, Pharmaceutical industry -- Licensing agreements, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Management, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Alliances and partnerships, Cooperative agreement for product development, Company business management, Company licensing agreement, Banking, finance and accounting industries, Business, Business, international
Abstract

Unlike some of its competitors, Swiss pharmaceutical firm Roche Holding Ltd. is choosing to focus on the development of high cost drugs that are marketed primarily to specialty doctors instead of the mass market products that are often seen as sure money-makers. The low marketing budgets required for specialty drugs and the better odds of such products being picked up by cash-strapped governments and employers, are two reasons behind the company's strategy.

Published
2004

38. Roche's net rises strongly, buoyed by cancer drugs

Author

Greil, Anita

Subjects
Roche Holding AG -- Company sales and earnings, Roche Holding AG -- Mergers, acquisitions and divestments, Roche Holding AG -- Subsidiaries, divisions and units, Roche Holding AG -- Product information, Genentech Inc. -- Product information, Genentech Inc. -- Finance, Biological products industry -- Product information, Biological products industry -- Finance, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Subsidiaries, divisions and units, Pharmaceutical industry -- Product information, Company product acquisition, Company financing, Company acquisition/merger, Company earnings/profit, Banking, finance and accounting industries, Business, Business, international
Abstract

Roche Holding AG doubles its first-half net profits thanks to strong sales of its cancer drugs and a hefty pre-tax gain that resulted from the company's having called in a bond issue. Established cancer medications, MabThera and Herceptin performed well, as did Avastin, the more recently introduced treatment for colorectal cancer.

Published
2004

39. Tracking the West Nile virus; two technologies vie to win new market after government orders blood supply screened

Author

Chase, Marilyn and Hamilton, David P.

Subjects
Roche Holding AG -- Product information, Chiron Corp. -- Product information, Gen-Probe Inc. -- Product information, West Nile virus -- Testing, West Nile virus -- Control, Pharmaceutical industry -- Product information, Biological products industry -- Product information, Medical test kit industry -- Product information, Business, Business, general
Published
2003

40. U.S. clears AIDS treatment Fuzeon

Author

Fuhrmans, Vanessa

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding AG -- Product information, Trimeris Inc. -- Product information, Biotechnology industry -- Product information, Anti-HIV agents -- Laws, regulations and rules, Pharmaceutical industry -- Product information, Antiviral agents, Government regulation, Business, Business, general, Fuzeon (Medication) -- Laws, regulations and rules
Published
2003

41. Roche Holding says it won approval for hepatitis-C drug

Author

Fuhrmans, Vanessa

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Pegasys (Medication) -- Laws, regulations and rules
Published
2002

43. U.S. grants fast-track status in review of hepatitis C drug

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Hepatitis C -- Drug therapy, Business, Business, general, Pegasys (Medication) -- Laws, regulations and rules
Published
2002

45. Breast-cancer drug pairing shows promise for survival time

Author

Fuhrmans, Vanessa and Winslow, Ron

Subjects
Roche Holding AG -- Product information, Aventis S.A. -- Product information, Breast cancer -- Drug therapy, Pharmaceutical industry -- Product information, Business, Business, general, Xeloda (Medication) -- Research, Taxotere (Medication) -- Research
Published
2002

46. EU panel initially approves two drugs from company

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, European Union -- Laws, regulations and rules, Pegasys (Medication) -- Laws, regulations and rules, Tamiflu (Medication) -- Laws, regulations and rules
Published
2002

47. Roche's anti-HIV drug Fuzeon shows 2-year benefits

Author

Kaye, Donald

Subjects
Roche Holding AG -- Product information, HIV (Viruses) -- Care and treatment, HIV (Viruses) -- Product information, Pharmaceutical industry -- Product information, Health, Health care industry, Fuzeon (Medication) -- Product information, Fuzeon (Medication) -- Usage
Published
2004

48. Roche Holding's Tamiflu gets approval for prevention for flu

Author

Adams, Chris

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Influenza -- Drug therapy, Drug approval -- Planning, Business, Business, general, Tamiflu (Medication) -- Licensing agreements
Published
2000

49. Roche launches test for SARS virus

Subjects
Roche Holding AG -- Product information, Severe acute respiratory syndrome -- Diagnosis, Pharmaceutical industry -- Product information, Health, Health care industry
Published
2003

50. Small but powerful

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Laboratory equipment -- Product information, Laboratories -- Equipment and supplies, Laboratories -- Product information
Abstract

The CoaguChek XS Plus System anticoagulation device for use at the point of care brings quality control through advanced built-in and independent liquid controls, and robust data-management and storage abilities [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results